{"filings":[{"id":102642,"accession_number":"0001493152-26-010070","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Q/C Technologies dismisses auditor Stephano Slack, appoints Grassi & Co.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Stephano Slack as independent auditor effective March 9, 2026.","Prior audit reports for FY2024 and FY2023 contained going concern emphasis paragraph.","No disagreements or reportable events during the period from October 2023 to dismissal.","New auditor Grassi & Co. engaged to audit FY2025 financial statements, effective immediately.","Company provided Stephano Slack with copy of 8-K; Stephano Slack's reply letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102641,"accession_number":"0001493152-26-003440","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Q/C Technologies appoints OpenAI's Chelsea Voss to Board, enters consulting agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chelsea Voss appointed to Board; she is Member of Technical Staff at OpenAI, key contributor to GPT-4, ChatGPT, DALL·E 2, Codex.","Consulting agreement: $12,500/month fee, 212,500 RSUs, and 212,500 stock options at $5.097/share or FMV.","RSUs and options vest quarterly over 12 months; agreement term is 12 months unless earlier terminated.","Voss was introduced to the company by Martin Shkreli, affiliate of Ocean Avenue Holdings LLC, a consultant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118879,"accession_number":"0001493152-25-026798","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Q/C Technologies hires Martin Shkreli as strategic advisor; issues warrants and restricted shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Monthly consulting fee of $12,500 ($150,000 annually) to Ocean Avenue Holdings, Shkreli's entity.","Warrants to purchase 212,500 shares at $5.097 per share, vesting quarterly over 12 months.","212,500 restricted shares of common stock granted, also vesting quarterly over 12 months.","Term of consulting agreement is 12 months; Shkreli will advise on acquisitions, technology, and board introductions.","Shkreli joins James Altucher on the advisory team; company highlights optical computing focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118878,"accession_number":"0001493152-25-023596","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve reverse stock split (1:2–1:250), equity plan increase, and share issuance at Nov 14 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio from 1-for-2 to 1-for-250, with Board discretion.","Equity incentive plan expanded by 1,375,000 shares to total 1,400,000 shares.","Issuance of shares exceeding 20% of outstanding common stock approved, tied to prior financing agreements.","All four proposals passed; no other matters considered at special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118876,"accession_number":"0001493152-25-017104","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K/A","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Q/C Technologies awards 225,000 RSUs to directors and officers; some vest upon shareholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial grants fully vested on grant date: Silverman 8,644, Schriber 2,161, White 2,161, Friscia 2,161, Glass 1,080, Rauch 1,080.","Additional grants require stockholder approval to vest: Silverman 91,356, Schriber 22,839, White 22,839, Friscia 22,839, Glass 11,420, Rauch 11,420, Bernstein 25,000.","Amendment corrects omission in Original Report filed Oct 3, 2025.","Total RSUs: 225,000 issued under 2021 Equity Incentive Plan.","Grants cover Executive Chairman, directors, and VP of Finance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118877,"accession_number":"0001493152-25-016927","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","3.02","3.03","5.02","9.01"],"status":"ready","headline":"QCLS amends Series H preferred terms, waives registration failure; hires James Altucher as consultant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 400k warrants to James Altucher/Z-List Media with exercise prices $5-$10 over 2-year term.","Registration deadline extended to 30 days post-closing; previous failure and penalties waived.","200k RSUs each to 6 executives/directors (Silverman, Schriber, White, Friscia, Glass, Rauch); some vest immediately.","Certificate of Designations amended to broaden Excluded Securities to 15% of common + convertible shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135417,"accession_number":"0001493152-25-015774","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.03","1.01","7.01","9.01"],"status":"ready","headline":"TNF Pharmaceuticals renamed Q/C Technologies, pivots to quantum-class computing with LightSolver license","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from TNF Pharmaceuticals to Q/C Technologies effective September 22, 2025.","Ticker changed from TNFA to QCLS on Nasdaq, effective at market open September 25, 2025.","Exclusive global rights to LightSolver's laser processing units for cryptocurrency applications.","Company claims LPUs reduce energy up to 90% vs GPUs and improve blockchain security.","Evaluating strategic options for legacy therapeutic assets isomyosamine and Supera-CBD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135420,"accession_number":"0001641172-25-027052","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"TNF Pharma closes $7M private placement at 44% premium; closes LPU acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed $7M private placement of 7,000 Series H preferred shares convertible to 1.4M common at $5.00/share, plus warrants for 1.4M shares at $5.00.","Conversion/exercise limited pending stockholder approval; placement agents include Rodman & Renshaw, H.C. Wainwright, and GPN.","Closed acquisition of LPU Holdings LLC, issuing Series I preferred stock convertible into 747,362 common shares.","Extended maturity of Series F and F-1 preferred stock to March 2, 2027 and removed amortization payments.","Common shares outstanding: 1,846,930 as of September 3, 2025; company plans to fund blockchain accelerator development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135418,"accession_number":"0001641172-25-026762","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K/A","filed_at":"2025-09-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"TNF Pharmaceuticals acquires LPU Holdings LLC for Series I Preferred Stock plus contingent milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["TNF to acquire 100% of LPU Holdings LLC; closing consideration is Series I Convertible Preferred Stock convertible into 747,362 common shares.","Contingent milestone payments include 6.25%/5% of equity offering proceeds up to $50M and a one-time share payment representing 10% of fully diluted shares upon reaching $50M aggregate proceeds.","Additional $1.75M payment (cash/equity) if TNF market cap reaches $100M for 10 consecutive trading days after 90 days post-closing.","Concurrent equity offering of at least $7.5M at $5.00/sh (Series H preferred) is a condition to closing.","Acquisition includes a License Agreement with LightSolver Ltd. for technology rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135419,"accession_number":"0001641172-25-026167","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","1.02","3.02","3.03","5.03","5.02","7.01","9.01"],"status":"ready","headline":"TNF Pharma raises $7M, acquires LPU Holdings for crypto mining, ends sarcopenia trial","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$7M private placement: Series H convertible preferred (7% dividend, $5 conversion) and warrants for 1.4M shares at $5; expected close Sept 4, 2025.","Agrees to acquire LPU Holdings for Series I convertible preferred convertible into 747,362 shares at $0.001/sh; contingent milestones; license with LightSolver for crypto mining laser hardware.","Terminates Master Service Agreement with Prevail for Phase 2 sarcopenia/frailty trial; effective 30 days after Sept 2, 2025 notice.","Director changes: Uzonwanne resigns; Glass steps down as President (stays CMO/Board); Bernstein appointed to Board; Silverman named Executive Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152404,"accession_number":"0001641172-25-014103","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"TNF Pharmaceuticals shareholders approve 5x increase in authorized common shares and reverse split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 250M to 1.25B, filed June 6, 2025.","Stockholders approved reverse stock split at ratio 1-for-2 to 1-for-100, board discretion, within one year.","Series F and F-1 preferred stock stated value increased from $1,000 to $1,100 per share, board may increase up to $1,250.","All six director nominees elected; auditor ratification approved.","Voting results: ~6.3M for share increase, ~6.4M for reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152403,"accession_number":"0001641172-25-009514","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"TNF Pharmaceuticals amends bylaws to lower stockholder vote threshold for non-director matters","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved First Amendment to Bylaws on May 9, 2025, effective immediately.","For non-director matters, vote required reduced from majority of voting power present to majority of votes cast (excluding abstentions and broker non-votes).","Corresponding change made for class votes on non-director matters.","Director election standard remains plurality of voting power present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152402,"accession_number":"0001641172-25-003829","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"TNF Pharmaceuticals sets 2025 Annual Meeting for May 20; proposal deadline April 18","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting will be held virtually on May 20, 2025 at 10:00 a.m. Eastern.","Deadline for Rule 14a-8 stockholder proposals is April 18, 2025, close of business.","Deadline for director nominations and universal proxy notices also April 18, 2025.","Meeting date changed by more than 30 days from 2024 anniversary, triggering new deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171239,"accession_number":"0001493152-25-011160","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TNF Pharma receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on March 17, 2025 for failure to maintain minimum $1.00 bid price over 30 consecutive business days.","Compliance period of 180 calendar days until September 15, 2025; must have $1.00 closing bid for 10 consecutive days.","If not cured, may get additional 180 days by meeting other listing standards and providing intent to cure, e.g., reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171238,"accession_number":"0001493152-25-009717","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TNF Pharmaceuticals holds investor call on Isomyosamine R&D progress","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Conference call conducted March 6, 2025 to discuss research and development of lead compound Isomyosamine.","Transcript furnished as Exhibit 10.1; no specific clinical or financial data provided in the available text.","Company noted it undertakes no obligation to update the materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188217,"accession_number":"0001493152-24-047742","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"TNF Pharmaceuticals stockholders approve 2.26M share increase to equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders re-elected all seven director nominees: Glass, Eagle, Schreiber, Silverman, Uzonwanne, White, Friscia.","Equity plan share reserve increased by 2,259,060 to 2,500,000 total, approved with 2.92M for and 116K against.","Stephano Slack LLC ratified as independent auditor for FY 2024 with 3.74M votes for.","Adjournment proposal approved with 3.42M votes for to permit further solicitation if needed.","Voting results final; no other matters considered at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188216,"accession_number":"0001493152-24-040276","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"TNF Pharma raises $600k via private placement at 20% premium; CRO partner engaged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 283,019 shares at $2.12/share (120% of 30-day VWAP) to Prevail Partners, gross proceeds $600k.","Proceeds for working capital; may be used to pay Prevail InfoWorks invoices under an August 2024 services agreement.","Prevail InfoWorks engaged as CRO for upcoming Phase 2 sarcopenia/frailty study of MYMD-1 TNFα inhibitor.","Press release states company is fully funded for clinical trials for next two years.","MYMD-1 previously met primary endpoints in a small Phase 2 sarcopenia study (2023) reducing chronic inflammatory markers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188215,"accession_number":"0001493152-24-039556","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"TNF Pharma replaces auditor Morison Cogen with Stephano Slack; prior reports include going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Morison Cogen resigned on Sept 30, 2024, citing its exit from public company audit services.","Audit committee appointed Stephano Slack as independent auditor for FY 2024, effective Oct 3, 2024.","No disagreements or reportable events occurred with Morison Cogen in fiscal years 2022 and 2023.","Morison Cogen's prior reports contained a going concern emphasis paragraph due to recurring losses.","Morison Cogen provided a letter (Exhibit 16.1) agreeing with the disclosures in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204705,"accession_number":"0001493152-24-037819","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"TNF Pharmaceuticals sets 2024 annual meeting for Nov 25; deadlines for proposals and nominations announced","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 annual meeting scheduled for November 25, 2024; record date October 18, 2024.","Stockholder proposals for inclusion in proxy under Rule 14a-8 must be received by October 3, 2024.","Nominations and other business outside Rule 14a-8 must be submitted by October 3, 2024.","Universal proxy rule notices for non-company nominees also due by October 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204704,"accession_number":"0001493152-24-032169","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"TNF Pharmaceuticals amends Series G Preferred Stock dividend calculation method","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment changes how in-kind dividends (additional Preferred Stock shares) are determined.","Certificate of Amendment filed with Delaware Secretary of State on August 8, 2024.","Amendment approved by Required Holders (majority of outstanding Preferred Stock).","Other terms of Series G Preferred Stock and related documents remain unchanged.","Event modifies rights of security holders under Item 3.03."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204703,"accession_number":"0001493152-24-029243","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"TNF Pharmaceuticals shareholders approve 15x increase in authorized common stock to 250M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 16,666,666 to 250,000,000; amendment filed July 25, 2024.","Shareholders also approved issuance of shares underlying Series F-1 and G Preferred and warrants for Nasdaq Rule 5635 compliance.","Share Increase Proposal vote: 819,760 for, 73,259 against, 12,851 abstain.","Ratification of Morison Cogen as independent auditor for FY2024 passed with 1,536,758 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204702,"accession_number":"0001493152-24-029227","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"MyMD Pharma rebrands to TNF Pharmaceuticals; ticker changes to TNFA on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from MyMD Pharmaceuticals to TNF Pharmaceuticals effective July 22, 2024.","Common stock began trading under new ticker 'TNFA' on Nasdaq effective July 24, 2024, replacing 'MYMD'.","Rebranding aligns with therapeutic focus on TNF-alpha inhibition; lead candidate MYMD-1 unchanged.","No change to CUSIP or shareholder action required; stockholder approval was not needed.","Company plans mid-stage clinical trials of MYMD-1 for sarcopenia following positive Phase 2 results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221552,"accession_number":"0001493152-24-024960","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"MyMD Pharmaceuticals increases authorized Series G Preferred shares from 8,950 to 12,826,273 for in-kind dividends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 17, 2024, MyMD filed a Certificate of Amendment to increase authorized Series G Convertible Preferred Stock from 8,950 to 12,826,273 shares.","The amendment enables payment of dividends 'in kind' in the form of additional Preferred Stock shares, per Section 3 of the Certificate of Designations.","The amendment was approved by Required Holders and became effective upon filing with the Delaware Secretary of State.","The Company had previously entered into a Securities Purchase Agreement on May 20, 2024 for sale of Preferred Stock and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221546,"accession_number":"0001493152-24-024548","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K/A","filed_at":"2024-06-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"MyMD Pharmaceuticals files 8-K/A to correct terms of ~$13.9M private placement of preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected typographical errors in terms of Series G and Series F-1 Preferred Stock and Warrants from May 20, 2024 private placements.","Private placements expected to raise approx. $13.9M gross ($8.9M Series G, $5.0M Series F-1).","Preferred stock convertible at $1.816/share, with 10% annual dividend; redemption beginning Dec 2024.","Company must hold stockholder meeting by Aug 1, 2024 to seek approval for share issuance above 19.99% and increase authorized shares.","Net proceeds to be used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221551,"accession_number":"0001493152-24-024046","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["1.01","3.03","5.02","5.03","8.01"],"status":"ready","headline":"MyMD appoints Glass as President/CMO, Friscia to board; Chapman departs; preferred shares increased","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mitchell Glass, M.D. appointed President & CMO effective June 13, 2024; no additional compensation.","Stephen Friscia appointed to board of directors, nominated by PharmaCyte Biotech per SPA.","Christopher Chapman, M.D. resigned as President, CMO and director effective June 14, 2024; separation includes $125K installments, $25K one-time, COBRA, option acceleration.","Amendment filed to increase authorized Series G Preferred shares from 8,950 to 12,826,273 for in-kind dividends.","Chapman's departure amicable; he will focus on Telomir Pharmaceuticals (TELO)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221550,"accession_number":"0001493152-24-021143","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"MyMD completes $14M private placement of Series G and F-1 preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $14 million from two concurrent private placements announced May 20.","Issued 8,950 shares Series G and 5,050 shares Series F-1 preferred, each convertible at $1.816/share.","Series G warrants cover up to ~9.86M shares; Series F-1 warrants cover ~2.37M shares, all at $1.816.","Preferred stock certificates of designations filed May 21; offering closed May 23.","Proceeds used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221549,"accession_number":"0001493152-24-020828","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"MyMD raises $13.9M via Series G & F-1 preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8.9M (Series G) and $5.0M (Series F-1) from private placement of convertible preferred and warrants at $1.816/share.","Series G preferred pays 10% dividend (15% on trigger), redeemable at company's option. Series F-1 mandatory redemption in 8 monthly installments from Oct 2024.","Existing Series F preferred maturity extended to Dec 31, 2024, and installment schedule amended via omnibus waiver and amendment.","Company must hold stockholder meeting by Aug 1, 2024, to approve issuance >19.99% of outstanding shares and increase authorized shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221548,"accession_number":"0001493152-24-015199","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MyMD CSO Dr. Adam Kaplin resigns effective immediately; no disagreement cited","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Adam Kaplin resigned as Chief Scientific Officer on April 15, 2024, effective immediately.","Resignation not due to any disagreement with the company, management, or board.","No replacement named; company's future CSO plans are undisclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221547,"accession_number":"0001493152-24-013870","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["1.01","3.03","5.02","5.03","9.01"],"status":"ready","headline":"MyMD defers preferred stock payments, amends certificate to grant voting rights and board seat to preferred holders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deferred March and April 2024 installment payments on Series F Preferred Stock to May 1, 2024, and waived related breaches.","Amended Certificate of Designations: preferred shareholders get as-converted voting rights at $60.21 conversion price.","Preferred shareholders granted right to elect one director by June 30, 2024.","Board increased from 6 to 7; Mitchell Glass appointed as director, elected by preferred holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241079,"accession_number":"0001493152-24-011310","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K/A","filed_at":"2024-03-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"MyMD corrects authorized share count to 16.7M common, 66.7M total via Delaware filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed Certificate of Correction on March 26, 2024 to fix an inadvertent error in authorized share numbers.","Corrected Article IV to state 16,666,666 authorized common shares and 66,666,666 total authorized shares.","Amendment amends March 7, 2024 8-K; no other changes to original report.","Corporate charter remains unchanged except for the numeric correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241082,"accession_number":"0001493152-24-009220","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"MyMD Pharmaceuticals reincorporates from New Jersey to Delaware","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Merger effective March 4, 2024; no change in company name, business, management, or fiscal year.","Stockholders approved reincorporation at 2023 annual meeting; common stock retains same CUSIP and symbol MYMD.","No exchange of stock certificates required; shares automatically convert on a 1:1 basis.","Rights of stockholders now governed by Delaware General Corporation Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241081,"accession_number":"0001493152-24-008824","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MyMD Pharmaceuticals regains Nasdaq minimum bid price compliance after reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on March 4, 2024 that it has regained compliance with Listing Rule 5550(a)(2).","Deficiency flagged Oct 11, 2023 after shares failed to maintain $1.00 bid for 30 consecutive days.","Conducted a 1-for-30 reverse stock split on Feb 14, 2024; split-adjusted trading began Feb 15.","Minimum bid price of $1.00 maintained for 10 consecutive business days, requirement met on March 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241080,"accession_number":"0001493152-24-006163","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"MyMD Pharmaceuticals effectuates 1-for-30 reverse stock split to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-30 ratio effective Feb 14, 2024 at 4:05 p.m. EST.","Outstanding shares reduced from ~62.7M to ~2.09M; authorized shares reduced from 500M to 16.67M.","Common stock begins trading on split-adjusted basis Feb 15 under same ticker MYMD; new CUSIP 62856X201.","Fractional shares rounded up to nearest whole share; proportional adjustments to warrants, preferred stock, and equity awards.","Company states split is intended to maintain compliance with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258564,"accession_number":"0001493152-23-043794","cik":1321834,"company_name":"Q/C TECHNOLOGIES, INC.","ticker":"QCLS","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MyMD Pharma gains FDA clearance for Phase 2 trial of oral MYMD-1 in rheumatoid arthritis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for Phase 2 trial of oral MYMD-1 (TNF-α inhibitor) in rheumatoid arthritis.","Trial planned for Q1 2024; will enroll ~60 patients with active RA at 1050 mg oral dose.","Preclinical data: MYMD-1 reduced disease severity by 47% vs 37% for Enbrel (etanercept).","MYMD-1 could become first FDA-approved orally administered TNF-α inhibitor for RA.","RA affects ~1.5M Americans with annual societal cost estimated over $40 billion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33848281.02015112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}